Amphotericin B microspheres: A therapeutic approach to minimize toxicity while maintaining antifungal efficacy

Journal of Microencapsulation

Volumn 26, Issue 7, 2009, Pages 580-587

  Angra, Pawan K ^a   Oettinger, Carl ^b   Balakrishna Pai, S ^a   D'Souza, Martin J ^a  

^a MERCER UNIVERSITY   (United States)

^b Dialysis Clinic Inc   (United States)

Author keywords

Amphotericin B; Bovine serum albumin; Microspheres; Polymers; Spray drying

Indexed keywords

AMFOCAN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; BOVINE SERUM ALBUMIN; HEMOGLOBIN; MACROGOL 2000; MICROSPHERE; POTASSIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; BROTH DILUTION; CONTROLLED STUDY; CROSS LINKING; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; PARTICLE SIZE; TOXICITY; ZETA POTENTIAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; ERYTHROCYTES; HUMANS; MICROSPHERES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 70449338200     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040902797516     Document Type: Article

References (36)

1. Atkinson AJBJE. 1978. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 13:271-276.
2. Benedetti E, Gruessner AC, Troppmann C, Papalois BE, Sutherland DE, Dunn DL, Gruessner RW. 1996. Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome. J Am Coll Surg 183:307-316.
3. Branch R. 1988. Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med 148:2389-2394.
4. Burgess JBR. 1972. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med 53:77-84.
5. Carlson KC, Mehlmauer M, Evans S, Chandrasoma P. 1987. Cryptococcal cellulitis in renal transplant recipients. J Am Acad Dermatol 17:469-472.
6. Carnevale NT, Galgiani JN, Stevens DA, Herrick MK, Langston JW. 1980. Amphotericin B-induced myelopathy. Arch Intern Med 140:1189-1192.
7. Chuck SL, Sande MA. 1989. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 321:794-799.
8. Chugh KS, Sakhuja V, Jain S, Singh V, Tarafdar A, Joshi K, Gupta KL, Minz M. 1992. Fungal infections in renal allograft recipients. Transplant Proc 24:1940-1942.
9. Correia FM, Petri DF, Carmona-Ribeiro AM. 2004. Colloid stability of lipid/polyelectrolyte decorated latex. Langmuir 20:9535-9540.
10. Cutler JE. 1991. Putative virulence factors of Candida albicans. Annu Rev Microbiol 45:187-218.
11. D'Souza M, DeSouza P. 1998. Preparation and testing of cyclosporine microsphere and solution formulations in the treatment of polyarthritis in rats. Drug Dev Ind Pharm 24:841-852.
12. D'Souza M, Pourfarzib R. 1999. Improved efficacy of a microencapsulated macrophage colony stimulating factor and methotrexate in melanoma. Drug Dev Ind Pharm 25:585-592.
13. D'Souza MJ, DeSouza PJ. 1995. Site specific microencapsulated drug targeting strategies to the liver and the gastrointestinal tract. Adv Drug Del Rev 17:247-254.
14. D'Souza MJ, Jin Z, Oettinger CW. 2005. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-kappaB. J Interferon Cytokine Res 25:311-320.
15. Escabi-Mendoza JE, Martinez-Diaz JD, Aviles-Rivera ED. 2006. Perflutren microspheres for contrast echocardiography in a bloody pericardiocentesis. Tex Heart Inst J 33:214-217.
16. Gerber DA, Oettinger CW, D'Souza M, Milton GV, Larsen CP, Pearson TC. 1995. Prolongation of murine cardiac allograft survival by microspheres containing TNF alpha and IL1-beta neutralizing antibodies. J Drug Target 3:311-315.
17. Green M, D'Souza MJ, Holbrook JM, Wirtz RA. 2004. In-vivo and in-vitro evaluation of albumin-encapsulated primaquine diphosphate prepared by nebulization into heated oil. J Microencapsulation 21:433-444.
18. Haswani DK, Nettey H, D'Souza MJ, Oettinger CW. 2007. In vitro evaluation and targeting of E. coli internalized by endothelial cells using albumin microspheres loaded with gentamicin. Drug Dev Ind Pharm 33:181-190.
19. Haswani DK, Nettey H, Oettinger C, D'Souza MJ. 2006. Formulation, characterization and pharmacokinetic evaluation of gentamicin sulphate loaded albumin microspheres. J Microencapsulation 23:875-886.
20. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. 1983. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 75:476-481.
21. Jabbour N, Reyes J, Kusne S, Martin M, Fung J. 1996. Cryptococcal meningitis after liver transplantation. Transplantation 61:146-149.
22. Murray L, 2006. Redbook 2006 pharmacy's fundamental reference. Montvale, NJ: Thomson.
23. NCCLS, 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Wayne, PA: NCCLS.
24. Odds FC. 1985. Candida albicans proteinase as a virulence factor in the pathogenesis of Candida infections. Zentralbl Bakteriol Mikrobiol Hyg [A] 260:539-542.
25. Odds FC. 1994. Pathogenesis of Candida infections. J Am Acad Dermatol 31:S2-S5.
26. Oettinger C, D'Souza M. 2003. Microencapsulation of tumor necrosis factor oligomers: A new approach to proinflammatory cytokine inhibition. J Interferon Cytokine Res 23:533-543.
27. Oettinger CW, D'Souza MJ, Akhavein N, Peer GT, Taylor FB, Kinasewitz GT. 2007. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kappaB. J Microencapsulation 24:337-348.
28. Paterson DL, Singh N. 1999. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 78:123-138.
29. Ruiz-Arango A, Landolfo C. 2008. A novel approach to the diagnosis of left atrial appendage thrombus using contrast echocardiography and power Doppler imaging. Eur J Echocardiogr 9:329-333.
30. Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Raposo R, Mendez MT, Torrado-Santiago S, Torrado JJ. 2004. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 48:3246-3252.
31. Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Torrado- Santiago S, Torrado JJ. 2005. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. J Drug Target 13:225-233.
32. Vieira DB, Carmona-Ribeiro AM. 2008. Cationic nanoparticles for delivery of amphotericin B: Preparation, characterization and activity in vitro. J Nanobiotechnol 6:6.
33. William HT, Bennett RE. 1963. Streptomyces nodosus sp. N., the Amphotericin-producing organism. J Bacteriol 85:436-439.
34. Wong-Beringer A, Jacobs RA, Guglielmo BJ. 1998. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 27:603-618.
35. Young RF, Gade G, Grinnell V. 1985. Surgical treatment for fungal infections in the central nervous system. J Neurosurg 63:371-381.
36. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med 104:234-240.